Version May 2024
Nail dystrophy: Topical: Apply once daily before bedtime to affected nail(s)
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined: Dermatologic: Skin irritation, stinging of the skin
Use with deep, open, or profusely bleeding wounds
Concerns related to adverse effects:
• Skin irritation: May sting upon application; discontinue use if redness or other signs of irritation occur.
Special populations:
• Isocyanate sensitization: Patients sensitized to isocyanate should not use poly-ureaurethane.
Other warnings/precautions:
• Flammable: Formulation is flammable; do not expose to high temperatures or near open flame. Use in a well-ventilated area.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, topical:
Nuvail™: 16% (15 mL)
No
Apply evenly to affected nail plate, proximal and lateral folds, and distal tip; allow to dry completely. Clean affected nails with nail polish remover once weekly. Use of other topical products before application of poly-ureaurethane may prevent film formation and reduce effectiveness. To avoid staining, avoid contact with finished surfaces (eg, furniture, counter tops).
Nail dystrophy: Management of signs and symptoms of nail dystrophy such as nail splitting and nail fragility for intact or damaged nails.
None known.
There are no known significant interactions.
Biocompatible, polymeric solution; forms uniform film that protects nail from abrasion, friction, and moisture
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
